Trial Profile
A multicenter, double-blind, randomized, placebo-controlled study of MK0431 in patients with type 2 diabetes mellitus who have inadequate glycemic control.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Feb 2014 Results published in the Drugs and Aging.
- 29 Jan 2009 Actual patient numbers changed from 500 to 530 as reported by ClinicalTrials.gov.
- 29 Jan 2009 Actual initiation date changed from Mar 2006 to Apr 2006 as reported by ClinicalTrials.gov.